You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Equiscreen.

NanoViricides (NNVC) Nears Critical Inflection Point with NV-387 Phase 2 Trials That Could Lead to Multi-Billion-Dollar Potential as Zacks Small Cap Research Issues $7 Valuation!

biotech

NanoViricides (NYSE: NNVC) is turning heads in the biotech world as the company is advancing its lead drug candidate NV-387 into Phase 2 trials for MPox, targeting the most recent outbreaks and potential U.S. biodefense applications. 


Leveraging its nanomedicine platform, NV-387 has demonstrated broad antiviral activity in preclinical models against measles, influenza, RSV, and orthopoxviruses. 


With orphan drug designation applications in progress and dual-track trials planned, NNVC is strategically positioned to capture multiple markets while delivering a first-of-its-kind broad-spectrum antiviral therapy!


According to Zacks Small Cap Research, the combination of NV-387’s safety record, proven efficacy in animal models, and regulatory strategy offers a compelling investment case. 


Zacks highlights the upside potential from government stockpile procurement, orphan drug incentives, and BARDA funding, which could provide non-dilutive capital and accelerate commercial adoption. 


With these catalysts on the horizon, NV-387 could become an essential therapy for viral threats worldwide and could make NNVC a breakout story in the biotech space next year.


Learn why NNVC is on the verge of redefining the antiviral market

We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.

We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $6,500 and was received/will be received from Interactive Offers.

This communication should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) and Interactive Offers.

We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.

This disclosure is made as of 01/12/2026.

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431


Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.

Behind the Markets


You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here.


Today's Bonus Content: Top 10 AI Stocks to Buy In January

 (By clicking this link you agree to receive emails from Trading Tips and our affiliates. You can opt out at any time. - Privacy Policy)